Clinical data and follow up in the patients treated. The visual acuity of the inflamed eye (right eye (od), left eye (os) or if both eyes had the same VA ou are listed)
| Infusions at week | Re-treatment at week | Treatment at baseline | Treatment after infliximab | Diagnosis | VA at baseline | VA after treatment | Follow up (weeks) | Duration of flare (days) | Flare up (month) |
|---|---|---|---|---|---|---|---|---|---|
| *In the patient with TINU syndrome no remission was achieved. | |||||||||
| 0 | None | 32.5 mg/day prednisone+20 mg MTX | 15 mg MTX | HLA-B27 | 20/100 | 20/30 | 70 | 7 | 5 |
| 0/2/6 | 26/28/32 | 12.5 mg MTX | 12.5 mg MTX | HLA-B27 | 20/40 | 15/20 | 82 | 2 | 6 |
| 0/2/6 | None | 17.5 mg/day prednisone +15 mg MTX | 12.5 mg MTX | HLA-B27 | 20/25 | 15/20 | 78 | 5 | 5 |
| 0/2/6 | None | 20 mg MTX+2 g CellCept+steroid drops | 20 mg MTX+2 g CellCept | HLA-B27 | 20/125 | 20/60 | 8 | 42 | – |
| 0/2/6 | None | 17.5 mg MTX | 15 mg MTX | HLA-B27 | 20/20 | 20/20 | 48 | 7 | 6 |
| 0/2/6 | 18/22/28/33 | 10 mg MTX+2 g CellCept+steroid drops | 12.5 mg MTX | JIA | 20/25 ou | 20/25 ou | 36 | 35 | 1 |
| 0/2/6 | 10/14/18/22/26 | Leflunomide | Leflunomide | JIA | 20/200 | 20/80 | 30 | 42 | 4 |
| 0/2/6 | 20/28 | Cyclophosphamide+prednisone 25 mg/day | Prednisone 12.5 mg/day | Scleritis | 20/200 od, CF os | 20/60 od, CF os | 30 | 90 | – |
| 0/2/6 | 10 | 10 mg/day prednisone+15 mg MTX | 10 mg/day Prednisone+15 mg MTX | TINU | 20/200 od, CF os | 20/200 od, CF os | 22 | * | |